Verified, then logged.
Sun 22 Nov 2026 · 00:21 KST / 15:21 UTC한국어 | ENSearch /

01 / AI · Analysis

HITS signs KAIST drug research MOU for HyperLab AI programme

An AI platform company and a research group covering the full drug development cycle join one programme

A multichannel pipette and well plates sit on a university drug-discovery lab bench while an out-of-focus researcher, seen from behind, studies a protein structure on a monitor. AI-generated image

HITS, an AI bio-platform company, said on 9 Nov 2026 that it signed a memorandum of understanding (MOU) with AI-CRED, a drug development research group at KAIST, to run the HyperLab AI Scientist Partner Programme, AI Times reported. KAIST is the Korea Advanced Institute of Science and Technology, a South Korean research university. Kim Woo-youn heads HITS.

AI Times, a South Korean AI news outlet, described the agreement as research support that uses an AI platform. Its core is that a platform company and a research group covering the full drug development cycle are tied into one programme.

The starting point for reading the agreement is the research scope of AI-CRED.

A research group spanning the full drug development cycle

AI-CRED's stated aim is to integrate AI technology with the full drug development cycle, according to AI Times. It is a KAIST-led national strategic convergence research group, and Lee Hee-seung is its director.

The same report listed its research fields as AI-based protein design, omics analysis and candidate compound structure design. Omics is the analysis of the full set of molecules in a living organism. The group also works on drug delivery system (DDS) development, preclinical research, the stage before testing in humans, and efficacy evaluation.

Research staff named in the agreement

Doctoral students and postdoctoral researchers at AI-CRED are the members named in the description of the agreement, according to the report. The agreement's own name refers to an AI scientist partner programme.

The research fields AI Times listed run from protein design to preclinical evaluation. The substance of the agreement is which of those stages HITS's AI platform is used in.